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ABSTRACT

Public health relevance. Homocysteine (HCY) is an inflammatory marker that can potentially be used as a biomarker of subclinical cardiovascular disease (CVD) risk among women of reproductive age.
The objective of this study was to determine if higher concentrations of HCY are associated with subclinical cardiovascular disease (CVD) (carotid intima-media thickness (IMT), pulse wave velocity (PWV) and blood pressure) among women 4 to 12 years after pregnancy. Our second aim was to determine if the concentrations of HCY differ between women with term and preterm births.
Methods. This was a cross-sectional study of 100 women with a prior term (N=51) or preterm (N=49) births participating in The Women and Infant Study of Healthy Hearts (WISH study) who completed a structured interview and donated a sample of blood. Carotid artery intima-media thickness (IMT), carotid-femoral pulse wave velocity (PWV), blood pressure, HCY, and fasting lipids were measured 4 to 12 years after pregnancy. Linear regression models were used to assess whether HCY was associated with IMT, PWV, and blood pressure among reproductive age women. Univariate and multivariate analyses were used to evaluate a difference in mean concentrations of HCY between term and preterm groups.
Results. In a simple linear regression model, HCY concentration was positively associated with IMT, and systolic and diastolic blood pressure (p-values <0.05). After adjusting for age and race, a positive association persisted for diastolic blood pressure (DBP) (β=0.913 mmHg, p=0.049) but not for other endpoints. Paradoxically, HCY was a negatively associated with PWV, though the relationship was statistically nonsignificant. After adding atherogenic lipids, BMI, and preterm birth delivery status into the models with age and race, HCY remained positively associated with only DBP (β=0.893 mmHg, p=0.039). Multivariate analysis demonstrated that there were no differences in mean concentrations of HCY between preterm and term groups adjusting for age and race (p=0.803), which was similar to univariate analysis result (p=0.959).
Conclusion. This study demonstrated that HCY concentrations were positively associated with DBP but not with IMT, PWV, and SBP among reproductive age women 4 to 12 years after pregnancy. HCY concentrations were not different in women with term compared to preterm births.
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1.0 	Introduction
1.1.1	Cardiovascular Disease and Preterm Birth: Epidemiology and Public Health Burden
Cardiovascular disease (CVD) is the number one cause of death in the world, accounting for 17.5 million deaths annually or 31% of all deaths []. The World Health Organization (WHO) estimated that over three out of four CVD deaths take place in low- and middle-income countries []. According to the American Heart Association (AHA), CVD accounts for 1 in 3 deaths in the United States []. Even though CVD-related mortality has declined by 11.7% from 2003 to 2013, it remains the leading cause of deaths in the U.S. among both men and women []. Recognizing and predicting CVD risk in women is challenging as CVD presents itself differently between the sexes  ADDIN EN.CITE [, ]. Thus, recognizing CVD risk in women has important implications for the prevention of CVD in women, as there is a need to develop CVD risk scores and prevention approaches that are specific to women []. Among traditional CVD risk factors, pregnancy complications, which are unique to women, could play an important role in the future risk of CVD development []. Sattar et al. suggested that pregnancy complications could be used as a stress/litmus test to identify women at higher risk for CVD []. Thus, we aimed to study reproductive age women who had a history of term and preterm births in order to detect subclinical CVD a decade after pregnancy.
Preterm birth is defined as childbirth occurring after less than 37 weeks of gestation []. According to the World Health Organization in 2015, low-income countries have, on average, 12% of infants born preterm, whereas higher-income countries report preterm birth rates at 9% []. The National Vital Statistics Reports March of Dimes Prematurity Campaign (2015) reported that 9.66% infants born in the United States were born preterm []. Furthermore, the U.S has a wide disparity in the rate of preterm birth by ethnicity. Non-Hispanic Blacks have the highest preterm delivery rate compared to Non-Hispanic Whites and Hispanics, with preterm delivery rates of  13.4%, 9.1%, and 9.3%, respectively []. Women with a history of preterm delivery have an increased risk of CVD compared to those with term delivery  ADDIN EN.CITE []. Also, women who delivered preterm had an increased prevalence of cardiovascular risk factors including elevated atherogenic lipids (lipids that promote the build-up of fatty plaques in arteries), high blood pressure, metabolic syndrome, and greater intima-media thickness (IMT) compared to women with term delivery []. Several studies also suggested that  women with a history of preterm birth had elevated cholesterol before and during pregnancy [, ]. Moreover, placentas of women with preterm delivery manifest adverse changes in their vascular walls [, ]. These vascular changes may promote a cascade of events that lead to preterm delivery and increase the cardiovascular risk for these women.
1.1.2	Homocysteine (HCY) and Cardiovascular Risk
Several published reports have suggested that HCY is  a marker for  increased risk of CVD [, ]. HCY, a metabolite of methionine, is a naturally occurring amino acid found in blood plasma. Catabolism of HCY in the human body requires the presence of folic acid, as well as vitamins B6 and B12.  During  methionine deficiency, HCY can be recycled to methionine but when methionine levels are sufficient, HCY is converted into cysteine [, ]. The normal range of HCY concentrations in the plasma of healthy fasting people varies between 5 to 15 µmol/L when assessed with High-Performance Liquid Chromatography but 5 to 12 µmol/L when using immunoassay methods [, ]. Hankey et al. classified the severity of hyperhomocysteinemia based upon total plasma concentration as moderate (16–30 µmol/L), intermediate (31–100 µmol/L), and severe (more than 100 µmol/L) [].
Gibson et al. first reported vascular pathologies and thrombosis in patients with hyperhomocysteinemia []. McCully reported an association between elevated concentrations of HCY and atherosclerosis []. Since both these publications, high concentrations of HCY have attracted the attention of CVD researchers to elucidate further the link between HCY concentrations and CVD.
A meta-analysis by Wald reported a 20 to 30% increase in risk for ischemic heart disease with every 5 µmol/L increase in HCY concentrations []. A recent meta-analysis that evaluated  HCY concentrations and the risk of cardiovascular disease in prospective studies among the elderly found that every 5 μmol/L increase in HCY raised the risk of cardiovascular and coronary heart disease (CHD) mortality by 32% and 52% respectively []. If there is a direct link, homocysteine-lowering therapies such as folic acid, vitamin B6, and B12 supplementation would be expected to have a preventive effect on CVD []. However, two Cochrane Reviews reported no evidence of homocysteine-lowering interventions with vitamin B6, B9, and B12 preventing  cardiovascular events []. Similarly, a meta-analysis of clinical trials of folic acid, vitamin B12, and B6 supplementation on plasma HCY concentrations and the risk of CVD demonstrated HCY-lowering effect but did not find an effect on CVD prevention [].
Questions remain whether increased concentrations of HCY are directly associated with cardiovascular events. For example, existing meta-analyses focused mostly on participants older than 59 years of age with elevated mean concentrations of HCY above >10 µmol/L at different follow-up periods of time, ranging from 0.5 to 7.3 years [, ]. They also contained more men than women, with women mostly in the postmenopausal period [, ]. Furthermore, these studies looked at the effect of HCY-lowering supplementation on CVD health among older populations [, ]. Possibly, if they had started preventative interventions such as HCY-lowering supplementation before age 50, the intervention may have been effective.
Identification of individuals at high risk for mortality and CVD events, especially among reproductive age women, would be helpful for CVD prevention and would have tremendous public health significance. Due to the strong association between HCY and CVD events, we considered that elevated concentrations of HCY might increase early subclinical CVD in reproductive age women.
1.1.3	Proposed Mechanisms for Homocysteine to Increase CVD
HCY is thought to influence the development of CVD by several different mechanisms []. One mechanism involves elevated HCY concentrations reacting with the endothelium, platelets, nitric oxide, and smooth muscles causing oxidative stress, endothelial dysfunction, and platelet activation [, ]. Another mechanism involves activation of inflammation by HCY in smooth muscle cells, which causes an activation of T-cells that, in turn, elicit an immune response creating favorable conditions for the development of atherosclerotic plaque [, ]. In addition, Bian et al. reported that inflammation was involved in atherosclerosis through LDLc transcytosis across endothelial cells []. 
Investigators have used two measures, IMT and Pulse Wave Velocity (PWV) of blood vessels, to identify atherosclerosis during its early stages  ADDIN EN.CITE [, , ]. Although these methods showed a positive association with subclinical atherosclerosis, the relationship with HCY concentration was unclear  ADDIN EN.CITE [, ]. A retrospective study of 78 patients with carotid artery lesions demonstrated that HCY was positively correlated with IMT after adjusting for age []. Matangi et al. suggested to consider age as an important factor that impacts IMT (>1.0mm as being abnormal, and >1.2mm as being high risk) []. On the contrary, Ntaios et al. did not find any correlation of HCY with IMT in ischemic stroke patients []. We should interpret these results with caution due to the inherent limitations of the studies including their small sample sizes. Therefore, it is still unclear whether serum concentrations of HCY are positively associated with IMT.
PWV has been used in clinical settings to measure arterial stiffness,  which has been suggested to be a marker of vascular damage [, ]. In young European women (<30 years) PWV had a median (10-90 percentile) 6.1 m/s (5.3–7.1) and 6.4 m/s (5.2–8.0) between the ages of 30 to 40 years []. Whereas, people with higher CVD risk have increased PWV measures than the healthy population. A cross-sectional study by Yun et al. looked at the association of HCY with brachial-ankle pulse wave velocity, LDLc, and an inflammation profile among Korean healthy men; they found an association between HCY and advanced arterial stiffness in a subgroup analysis among participants with HCY concentrations >13 µmol/L []. Investigation of patients treated for hypertension and type 2 diabetes also demonstrated a positive correlation between HCY concentration and PWV []. However, several studies involving healthy people in France and Northern Ireland did not find a similar association, even though arterial stiffness as measured by PWV is a marker of early vascular disease  ADDIN EN.CITE [, ]. We should be cautious about interpreting these studies because the study in France included healthy adults [], whereas in Northern Ireland, the investigation focused on healthy schoolchildren []. Therefore, both of these studies may have failed to show a correlation because cardiovascular risk and arterial stiffness are typically manifested later in life.
1.1.4	Homocysteine and Blood Pressure
Studies have reported a positive association between HCY concentrations and systolic and diastolic blood pressure, especially among young population segments [, ]. Although the  mechanism remains unclear, a previously published cell culture study suggested that elevated concentrations of HCY leads to oxidative stress in  endothelium cells and reduces the vasodilator nitric oxide []. As a result, oxidative stress and reduction of nitric oxide could lead to increased peripheral resistance and elevated blood pressure. For example, a large prospective population study demonstrated a positive association between HCY and arterial stiffness among both normotensive and hypertensive groups as well as an increase in DBP and SPB of 0.7 and 1.2 mmHg in women for every 5 µmol/L  increase in HCY concentration []. Furthermore, comparisons between women who had the lowest and highest concentrations of HCY demonstrated a 3-fold increased risk for hypertension in the group with elevated HCY []. Thus, HCY concentrations may be positively associated with blood pressure abnormalities.
1.1.5	Factors Affecting Homocysteine Concentration
Several factors can affect the concentration of HCY. Jain et al. reported differences in HCY concentration with sex, women had lower mean HCY concentrations compared to men (10.94±7.05 vs. 18.88±14.7 μmol/L; p=0.032). []. These findings were consistent with other studies [, ]. The sex difference may be explained by  differences in muscle mass, vitamin levels, estrogen status and HCY conversion rate [, ]. Age, independent of estrogen concentration, is also a strong determinant of HCY concentrations, with a gradual increase in HCY concentrations occurring throughout the life span of both men and women  ADDIN EN.CITE [, , ]. Inflammatory processes, which occur with aging, could partially explain these observations. Singh and Newman found that inflammation increases with age, even in the absence of pathological stressors []. Gori et al. showed that interlukin-6 (IL-6), an inflammatory cytokine, was an independent predictor of HCY concentrations [].  Although it is not well understood why the elderly have higher concentrations, renal function may have an independent effect on HCY concentrations because the kidneys are responsible for almost 70 percent of HCY clearance []. Consequently, it is possible that reduced glomerular filtration later in life leads to higher concentrations of HCY. The Hordaland Homocysteine Study (HHS), investigating HCY concentrations in 18,000 men and women in Norway demonstrated that folate intake had a homocysteine-lowering effect, while coffee consumption and smoking were associated with an  elevated HCY concentration in the general population [, ].  Furthermore, this study demonstrated that 8.5% of participants in the general population had a mild elevation, 0.8% had moderate, and 0.02% had severe elevations in HCY concentrations [, ]. The prevalence of abnormal elevations in HCY concentrations in the United States was much lower than in Norway, which could be explained by the affect of widespread supplementation of white flour and cereal with folic acid in the US since 1998 []. Previously published studies reported that smoking cessation as well as the intake of folic acid and B vitamins have a homocysteine-lowering effect, without necessarily having a preventive benefit on adverse CVD events, except in the case of smoking cessation [, ]. 
Vitamin B6 and B12 deficiency increases HCY concentrations by reducing the activity of the enzyme pathways that metabolize HCY []. Several studies found that daily supplementation with folic acid, vitamin B6, and B12 decrease plasma HCY concentrations up to 28%. Moreover, genetic defects in the enzyme methylene tetrahydrofolate reductase (MTHFR), which is involved in HCY metabolism, has a broad impact on its concentration [, ]. A deficiency of  MTHFR  leads to an increase in HCY of 13 to 60 µM [, ]. HCY concentration can also be influenced by exposure to drugs and diseases that interfere with HCY metabolism or folate and vitamin B metabolism  ADDIN EN.CITE [, , , ].
1.1.6	Homocysteine and Pregnancy Outcomes
Elevated concentrations of maternal HCY are associated with adverse pregnancy outcomes such as preeclampsia, recurrent spontaneous abortions, low birth weight, and preterm birth  ADDIN EN.CITE [, ]. Cotter et al. found that elevated HCY was associated with a 3-fold increased risk for the development of severe preeclampsia and 4-fold increase for non-severe preeclampsia [, ]. While the exact mechanism is not well understood, one possible explanation may be that elevated concentrations of HCY compromise maternal vascular walls through endothelial dysfunction, including alteration of placental blood vessels  ADDIN EN.CITE [, , ].
Several reports describe the changes in HCY concentrations occurring during pregnancy. Dodds et al. reported that HCY concentrations decrease during pregnancy, with the lowest concentrations occurring during the second trimester, and then increasing during  the middle of the third trimester of pregnancy []. Mascarenhas et al. found that increased maternal HCY concentrations measured at the end of the first trimester (between 8 and 12 weeks) were significantly associated with adverse pregnancy outcomes including pregnancy losses, gestational hypertension, and preterm birth []. We hypothesize that HCY concentrations may also be associated with an increased risk for cardiovascular changes many years after pregnancy among reproductive age women.
A systematic review on the history of preterm birth and the subsequent development of CVD found that women who had a history of preterm birth demonstrated a 2-fold increased the risk of CVD mortality compared to those women with term delivery []. Furthermore, Rich-Edwards et al. reviewed physiological mechanisms that may contribute to the association between pregnancy complications such us preeclampsia and preterm birth with future CVD []. Adverse pregnancy outcomes and their history have been suggested to be used as a stress test to unmask women who are already at risk for CVD development [, ]. In addition, Rich-Edwards et al. report encourages studying pregnancy complications among reproductive age women to improve CVD risk-scoring system for women []. Our study would investigate whether elevated concentrations of HCY are associated with subclinical CVD among reproductive age women after a decade of pregnancy. By studying reproductive age women with a history of both term and preterm births, we could identify an informative period in postpartum years of these women when they are especially susceptible to subclinical CVD changes. Consequently, a proper strategy for screening, treatment, and prognosis needs to be developed in order to decrease the burden of CVD among these women, and our study proposes that HCY could be a biomarker of risk.
1.2	Objective
The first objective of the study was to detect if elevated concentrations of HCY are associated with subclinical CVD (IMT, PWV and blood pressure) among reproductive age women 4 to 12 years after pregnancy. The second objective was to determine if the concentrations of HCY differ between term and preterm group women a decade after pregnancy.
2.0 	MEthods
2.1.1	Participants
This was a subanalysis of women participating in the WISH Study (Women and Infant Study of Healthy Hearts. PI: Janet Catov, PhD), which is a prospective cohort study that assesses cardiovascular factors among women 4 to 12 years after pregnancy with preterm delivery, small for gestational age (SGA) delivery, or  with normal term delivery (total N=702 for parent study population). The University of Pittsburgh Institutional Review Board (IRB) approved all study procedures. Eligible participants were women who gave birth between 1997 and 2002 at Magee-Womens Hospital of UPMC Health System in Pittsburgh and were free of preeclampsia and gestational diabetes at the time of delivery. All participants signed informed consents. From the parent database, we extracted variables of interest, including IMT, PWV, SBP, DBP, and HCY concentrations. Our inclusion criteria for the cases were women with preterm birth (N=181). We included in the preterm group women who had evidence of placental pathology (N=119) as well as a control group of women with term deliveries with no placental pathology (N=457), in an attempt to gather a more severely affected case group and truly normal healthy control group []. Exclusion criteria included women who had SGA infants, race other than African American or white, gestational diabetes (N=11), triglycerides >400 mg/dL (N=2), and women with term births with placental pathology (N=64). From the two groups described above, we randomly selected two smaller subgroups based on convenience sampling for further analysis. We obtained a sample size of 100 participants who satisfied our inclusion and exclusion criteria (N=51 term, N=49 preterm).
2.1.2	Measures
A review of the medical records yielded a list of delivery characteristics, gestational age (estimated by prenatal ultrasound methods), and the first day of the last menstrual period. Standard methods were used to evaluate blood pressure; a tape measure (centimeters) was used to measure waist circumference at the umbilicus. All participants completed a structured interview, which included information about demographics and lifestyle including age, race/ethnicity, socio-economic status, smoking status, and medical history (BMI, waist circumference, blood pressure, and history of diabetes). Reproductive history included information about pregnancy, menstrual cycle, and information on menopause onset, where applicable.
2.1.3	Laboratory Measurements
At a research visit, occurring 4 to 12 years post pregnancy, B-mode ultrasound images of the right and left distal common carotid arteries, carotid bulb, and the first centimeter of the internal carotid artery were obtained in diastole. Using semi-automated edge-detection software (Artery Measurement System, Gothernburgh, Sweden), the lumen-intima and media-adventitia interfaces were identified and measured across 1 cm segments of the near and far walls of the common carotid artery, as well as the far wall of the carotid bulb and internal carotid artery. Reproducibility of IMT measures was excellent with an intraclass correlation coefficient between sonographers of ≥0.87, and between readers of 0.92. Images were read using the Brachial Analysis System software developed at Medical Imaging Applications, University of Iowa []. Automated Complior SP (Artech Medical, Pantin, France) was used to measure carotid-femoral PWV, which is the distance traveled by a pressure wave between right carotid and right femoral arteries divided by the time delay between respective waveforms. Three runs were recoded and then averaged for further analysis. The distance between arterial sites of interest was measured by tape over the body surface and calculated by the following formula: (carotid-femoral distance = ((suprasternal-umbilicus) + (umbilicus - femoral)) - (carotid-suprasternal)). Intraclass correlations were 0.75-0.95 for between-technician and 0.88-0.95 for within-technician comparisons. Further details on the methods were published by Catov et al. [].
	Fasting blood samples were drawn at the same study visit. Samples were analyzed at the Nutrition Laboratory in the Department of Epidemiology at the University of Pittsburgh. Blood samples were centrifuged; sera were aliquoted and stored at -70o C. Total cholesterol, high-density lipoprotein cholesterol (HDLc), and triglycerides were measured under standard enzymatic procedures  ADDIN EN.CITE []. LDLc was calculated by Friedewald estimation []. The coefficients of variation (CV%) were 1.3 to 6.5% for intra- and inter-assay variabilities. ApoB was analyzed by using a variation of the Boehringer Mannheim turbidimetric procedure and the CV% was 9.8%. HCY was measured spectrophotometrically on an Olympus AU400 using reagents obtained from Axis-Shield Diagnostics, Ltd (Dundee, UK). The intra- and inter-assay CV% were 2.8% and 6.3%, respectively.
2.1.4	Statistical Analysis
All statistical analyses were performed using SAS 9.4 version. Descriptive statistics, including mean, median, standard deviation (SD), and interquartile range (IQR) were computed for continuous variables. For categorical variables, frequencies and percentages were calculated. Histograms, quantile-quantile plots, and Kolmogorov-Smirnov tests were used to assess normality. Pearson’s correlations were used to assess associations between dependent and independent variables for normally distributed data and Spearman’s correlations were used to assess associations for non-normally distributed data. HCY, IMT, SBP, triglycerides, CRP, IL6, and BMI had non-normal distributions based on Kolmogorov-Smirnov test (p-values <0.05); therefore, these variables were log transformed for all subsequent analyses.
To assess whether HCY concentrations are significantly associated with IMT, PWV, and blood pressure, we performed simple and multivariate linear regressions. In Model 1 (simple linear regression), HCY was entered in the model as a predictor variable and IMT, PWV, SPB, and DBP were the outcomes. In Model 2 (multivariate linear regression), HCY was again entered as the predictor for the outcome variables; however, we adjusted for age and race. Model 3 added BMI and lipid profile (total cholesterol, HDLc, LDLc, triglycerides, and ApoB) as covariates, again adjusting for the above risk factors. Model 4 introduced a preterm birth status as a covariate in addition to adjusting for the risk factors from Model 4. In Model 4, we also checked for interactions between HCY and age as well as HCY and race to predict PWV.
Comparisons of categorical variables between preterm and term birth groups were analyzed by chi-square and Fisher’s exact test, when appropriate. Independent t-tests were used to compare normally distributed continuous variables between the two groups. Wilcoxon rank-sum tests were used for the analysis of non-normally distributed data. The Kruskal-Wallis H Test was used for determining statistically significant differences between two or more groups of an independent variable. We also used multivariate analysis to compare mean values between preterm and term groups adjusting for age and race. All statistics were a two-sided test at α=0.05 significance level.



3.0 	results
There were 100 participants in this study with a mean concentration of HCY at 7.64 (lower mean 5.94; upper mean 9.83) μmol/L. Furthermore, none of the participants had HCY concentration higher than 13 μmol/L. Demographic characteristics of the cohort are reported in Table 1.
In the univariate analyses of the entire cohort, HCY differed only by income levels, where income level between $20,000 and $50,000 had the highest median concentration of HCY and the lowest concentration of HCY was in income level greater than $50,000 (8.9 (IQR: 7.6, 10.5) vs. 6.95 (IQR: 6.1, 8.15) μmol/L; p=0.003) (Table 2). Significant positive correlations were found between HCY concentrations, and total cholesterol (r=0.205, p=0.043), LDLc (r=0.253, p=0.012), IMT (r=0.223, p=0.037), SBP (r=0.213, p=0.035), and DBP (r=0.22, p=0.03).  A summary of the Spearman correlations for HCY with various factors can be found in Table 3.
In a simple linear regression model, HCY was significantly positively associated with IMT, SBP and DBP (p-values <0.05), with about 7% of the variation in these variables explained by HCY (R2=0.07); whereas, HCY was negatively associated with PWV; however non-significantly (R2=0.01; p=0.467). Our multiple linear regression model showed a significant positive association only between HCY and DBP after adjusting for age and race (p=0.049). HCY remained showing a statistically nonsignificant negative association with PWV (p=0.095). Adjusting for age, race, BMI, and atherogenic lipids, HCY was significantly positively associated only with DBP (p=0.041) and HCY explained approximately 32% of variability in the model (R2=0.319). This significance and R2 did not change after adding the preterm status variable. The regression models with beta-coefficients and p-values are summarized in Table 4.
HCY did not differ between preterm and term groups (p=0.991) (Table 5). Despite the fact that women with preterm vs. term births had significantly higher mean total cholesterol (203 vs. 180 mg/dL, p=0.007), LDLc (122 vs. 107 mg/dL, p=0.039), and ApoB (95 vs. 84 mg/dL, p=0.044) concentrations; the preterm group did not have higher HCY concentrations. Detailed comparisons are reported in Table 5.
4.0 	discussion
A key finding of this study was that HCY was significantly positively associated with DBP after adjusting for age, race, lipid profile, and preterm birth status.  We also found that the mean concentrations of HCY were not different between preterm and term groups. This is partially supporting our hypothesis that HCY concentrations are associated with DBP, but not with IMT, PWV, and SBP among reproductive age women 4 to 12 years after a pregnancy. 
Previously published literature demonstrates that HCY is positively associated with both SBP and DBP, especially among younger aged participants  ADDIN EN.CITE [, , ]. Our findings are partially consistent with the previously published work, demonstrating a significant positive relationship between HCY and DBP. Preterm birth, BMI, and atherogenic lipids are risk factors for CVD, so they could explain the increase in DBP. Interestingly, HCY was significantly associated with changes in SBP only in the unadjusted model and in the models adjusted for age and race, but in the other models HCY was not associated with SBP, which conflicts with previously published studies  ADDIN EN.CITE [, , ]. One possible explanation may be that our sample population was younger and that the mean HCY concentration was lower than they were in the Hordaland Homocysteine Study []. Hordaland Homocysteine Study included both women who had a pregnancy history and those who did not []. Lastly, unknown confounding factors may have affected this association.
Although there has been little epidemiological evidence published on the link between HCY and IMT, HCY has been reported to be positively associated with IMT [, ]. We could not detect an association between HCY and IMT, which might be due to population differences. Previously published studies contained a diabetic population, as well as population with higher mean HCY concentrations [, ]. Our sample population was relatively young and had IMT measures (0.571 mm (lower mean 0.502; upper mean 0.650)) and HCY concentrations (7.64 μmol/L (lower mean 5.94; upper mean 9.83)) in healthy range (Table 2).
Several studies have reported a positive association between HCY and arterial stiffness  ADDIN EN.CITE [, , ]. Surprisingly, our results conflict with those from the literature because in our study PWV tended to decrease for every 1-unit increase in HCY. That relationship persisted when we adjusted for age, race, lipid profile and preterm birth status, though they did not achieve our chosen level of statistical significance (p<0.05). Tests for interaction effects between HCY and PWV as well as HCY and race yielded non-statistically significant results and therefore do not appear to explain the negative association between HCY and PWV. Normally, arterial stiffness increases among those with CVD risks. Unknown confounding factors may have affected our results that we were not able to explain.
The mean concentrations HCY decreased with increasing level of income, which was partially consistent with previously published literature []. Our results demonstrated that participants with middle incomes had the highest concentrations of HCY while the upper-income group had the lowest value of HCY. Although the mean concentrations of HCY were not strikingly different, the difference between low- and middle-income groups could be due to the social support provided by government for low-income categories. Therefore, the middle-income group may be more sensitive to higher HCY concentration than low-income group.
One limitation is that our study only recruited White and African American women; therefore, our results are not generalizable to men and individuals of other ethnicities. Another limitation is that women in our study had a history of only term and preterm births, so we cannot extrapolate to women with a history of other pregnancy complications such us preeclampsia, recurrent spontaneous abortions, and low birth weight. Moreover, our participants were recruited between 1997 and 2002 at Magee-Womens Hospital of UPMC Health System in Pittsburgh, after the institution of the widespread supplementation of white flour and cereal with folic acid in the US (1998). Therefore, the true mean concentrations of HCY could have been decreased due to this dietary intervention in this cohort. Not having access to information about whether vascular and lipid changes were present before or during pregnancy is another limitation. The strength of this study is that we adjusted for multiple covariates that are associated with HCY and/or vascular risk factors. Another strength is that our population came from a well-designed parent study where all samples and health data were collected in a uniform manner using standard protocols.
These findings open new directions for exploration. Future studies can include accessing health information before and during pregnancy to see if HCY concentrations could be associated with subclinical CVD measured by IMT, PWV, and blood pressure among reproductive age women. Furthermore, our blood samples were drawn 4 to 12 years after  pregnancy, while the literature suggests that maternal HCY drawn between 8 and 12 weeks of pregnancy has the potential to be associated with adverse pregnancy events []. Therefore, we should consider using HCY drawn during this period of pregnancy (coinciding with the timing of the first prenatal visit) to see if it associates with the development of a subclinical CVD.
5.0 	Conclusions
The results demonstrate that HCY concentrations were positively associated with DBP, but were not associated with IMT, PWV and SBP among reproductive age women 4 to 12 years after pregnancy. In addition, we found that HCY concentrations were not different between preterm and term groups. While these findings are limited to White and African American women, these results may be important for the development of future public health interventions and for computing CVD risk scores for young reproductive age women. HCY may potentially be associated with subclinical CVD as measured by DBP among reproductive age women. A large-scale longitudinal study is necessary to determine any relationship between HCY and IMT, PWV, and blood pressure.
6.0 	Public Health Significance
The findings of this study will benefit public health considering that CVD remains an important problem among women due to its impact on morbidity, mortality, and healthcare expenditures. Therefore, there is a definite need to find appropriate screening biomarkers that could predict cardiovascular risk in reproductive age women. Furthermore, new knowledge would help to advance existing knowledge about risk CVD factors that are unique for women and develop CVD risk scoring system for women. It would also help to develop preventative strategies for women at high risk, thus potentially decreasing the economic drain on public health and healthcare resources.










APPENDIX: TABLES




Table 1.  Demographic Characteristics of the Cohort.
	OverallN=100
Index pregnancy (1997-2002)Age, years mean (SD)African-American, N (%)Multiparous, N (%)	29.65 (6.56)28 (28.57)76 (77.55)
Study visitBody mass index (kg/m2)*Waist Circumference (cm)*Current Smokers, N (%)Systolic blood pressure (mm Hg)*Diastolic blood pressure (mm Hg)Menopause, N (%)Diabetes, N (%)	27.69 (23.36, 33.7)92.75 (85.1, 105.5)30 (30.61)108.17 (101, 114.33)70.44 (9.38)9 (9.18)2 (2.04)
Education, N (%)High school or lessCollege>College	37 (37.76))49 (50)12 (12.24)
Income, N (%)Less than $20,000$20,000-<$50,000$50,000 and greater	23 (25)29 (31.52)40 (43.48)
Menstrual cycle phase at study visit, N (%)<14 days of menses>=14 days of menses	41 (46.07)48 (53.93)
Laboratory measurementsTotal Cholesterol (mg/dL)HDL Cholesterol (mg/dL)Triglycerides (mg/dL)**LDL Cholesterol (mg/dL)C-Reactive Protein (µg/ml)**Apolipoprotein B (mg/dL)Interleukin 6 (pg/ml)**Homocysteine (μmol/L)**Intima-Media Thickness (mm)**Pulse Wave Velocity (m/s)	191.42 (39.80)55.35 (14.70)108.91 (60.72; 120.10)114.36 (34.33)2.20 (0.639; 7.60)89.17 (26.83)1.58 (0.736; 3.39)7.64 (5.94; 9.83)0.571 (0.502; 0.650)7.59 (1.37)
* - Non-normally distributed data
** - Log transformed and then exponentiated (mean, lower and upper mean values)









Table 2.  Univariate Analysis of homocysteine and categorical variables (N=100).
	Homocysteine
	Median (IQR)	P-value*
RaceBlackOthersCurrent SmokingYesNoMultiparousYesNoEducation High school or lessCollege>CollegeIncomeLess than $20,000$20,000-<$50,000$50,000 and greaterMenstrual cycle phase at study visit<14 days of menses>=14 days of mensesDiabetesYesNoMenopauseYesNo	8.05 (6.5, 10.45)7.3 (6.5, 8.5)7.7 (6.8, 10.6)7.35 (6.4, 8.5)7.2 (6.5, 8.55)8.05 (7.0, 9.7)7.8 (6.6, 9.4)7.2 (6.5, 8.5)7.15 (6.65, 10.1)7.1 (6.2, 8.5)8.9 (7.6, 10.5)6.95 (6.1, 8.15)7.1 (6.1, 8.4)7.5 (6.6, 9.65)7.3 (6.6, 8.0)7.4 (6.5, 8.95)8.1 (7.8, 11.5)7.3 (6.5, 8.9)	0.2870.1240.2540.689**0.003**0.1640.7920.123
*- Wilcoxon Signed-Rank Test
**- Kruskal-Wallis H Test






Table 3.  Correlation of Homocysteine with All Variables (N=100).
	Homocysteine
	R	P-value*
Age (years)Gestational Age (week)Body mass index (kg/m2)Waist Circumference (cm)Systolic blood pressure (mm Hg)Diastolic blood pressure (mm Hg)Total Cholesterol (mg/dL)HDL Cholesterol (mg/dL)Triglycerides (mg/dL)LDL Cholesterol (mg/dL)C-Reactive Protein (µg/ml)Apolipoprotein B (µg/ml)Interleukin 6 (pg/ml)Pulse Wave Velocity (m/s)Intima-Media Thickness (mm)	0.185120.011700.101700.099680.212820.219600.204920.06985-0.047830.253470.062770.194670.11596-0.062980.22300	0.0680.9080.3190.3290.0350.0300.0430.4940.6400.0120.5390.0550.3090.5690.037
*- Spearman correlation
Table 4.  Association of HCY and IMT, PWV and Blood Pressure (N=100).
Model 1	Homocysteineβ-coefficient (Standard error)	P-value	R2 
Intima-media thickness (mm)*Pulse Wave Velocity (m/s)Systolic Blood Pressure (mm Hg)*Diastolic Blood Pressure (mm Hg)	0.01595 (0.00640)-0.05214 (0.07138)0.01227 (0.00516)1.08721 (0.44289)	0.0150.4670.0190.016	0.0670.0070.0560.059
Model 2a			
Intima-media thickness (mm)*Pulse Wave Velocity (m/s)Systolic Blood Pressure (mm Hg)*Diastolic Blood Pressure (mm Hg)	0.00940 (0.00595)-0.11523 (0.06813)0.00905 (0.00523)0.91373 (0.45811)	0.1180.0950.0870.049	0.2640.1740.1150.084
Model 3b			
Intima-media thickness (mm)*Pulse Wave Velocity (m/s)Systolic Blood Pressure (mm Hg)*Diastolic Blood Pressure (mm Hg)	0.00368 (0.00545)-0.13344 (0.07052)0.00730 (0.00514)0.87894 (0.42380)	0.5020.0620.1590.041	0.4750.2550.2580.319
Model 4c			
Intima-media thickness (mm)*Pulse Wave Velocity (m/s)Systolic Blood Pressure (mm Hg)*Diastolic Blood Pressure (mm Hg)	0.00378 (0.00542)-0.13325 (0.07077)0.00748 (0.00518)0.89284 (0.42688)	0.4870.0640.1520.039	0.4870.2600.2600.320
a - Model 2 adjusted for age and race
b - Model 3 adjusted for Model 2, BMI and lipid profiles (total cholesterol, HDLc, LDLc, Apo B, and Triglycerides)
c - Model 4 adjusted for Model 3 and preterm risk factor
* - Log transformed variables with their log-transformed beta-coefficients
Table 5.  Demographic Characteristics of Term and Preterm Groups.
	TermN=51	PretermN=49	p-value*
Index pregnancy (1997-2002)Age, years mean (SD)African-American, N (%)Multiparous, N (%)	29.17 (6.18)16 (31.37)10 (10.2)	30.17 (6.97)12 (25.53)12 (12.24)	0.4510.5230.483
Study visitBody mass index (kg/m2)**Waist Circumference (cm)**Current Smokers, N (%)Systolic blood pressure (mm Hg)**Diastolic blood pressure (mm Hg)Menopause, N (%)Diabetes, N (%)	27.79 (22.32, 34.31)92.3 (81.7, 102.5)15 (29.41)108 (101.67, 112.67)69.77 (9.66)2 (3.92)2 (3.92)	27.48 (23.36, 32.38)93.6 (86.5, 107.3)15 (31.91)108.3 (101, 115.67)71.16 (9.12)7 (14.89)0 (0.0)	0.9150.6240.7880.5430.4690.0830.496
Education, N (%)High school or lessCollege>College	17 (33.33)28 (54.9)6 (11.76)	20 (42.55)21 (44.68)6 (12.77)	0.582
Income, N (%)Less than $20,000$20,000-<$50,000$50,000 and greater	14 (28.57)12 (24.49)23 (46.94)	9 (20.93)17 (39.53)17 (39.53)	0.291
Menstrual cycle phase at study visit, N (%)<14 days of menses>=14 days of menses	21 (42.86)28 (55.06)	20 (50.0)20 (44.94)	0.501
Laboratory measurements aTotal Cholesterol (mg/dL)HDL Cholesterol (mg/dL)Triglycerides (mg/dL)***LDL Cholesterol (mg/dL)C-Reactive Protein (µg/ml)***Apolipoprotein B (mg/dL)Interleukin 6 (pg/ml)***Homocysteine (μmol/L)***Intima-Media Thickness (mm)***Pulse Wave Velocity (m/s)	180.47 (37.05)53.90 (12.77)88.32 (86.75; 89.89)107.02 (32.27)2.57 (0.74; 8.87)83.66 (28.18)1.71 (0.81; 3.62)7.65 (5.80; 10.09)0.558 (0.495; 0.629)7.434 (1.51)	203.30 (39.63)56.93 (16.54)104.58 (102.87; 106.3)122.32 (35.05)1.87 (0.55; 6.36)95.15 (24.18)1.50 (0.69; 3.26)7.67 (6.12; 9.60)0.586 (0.512; 0.672)7.785 (1.16)	0.0070.4030.0990.0390.2600.0440.2990.9910.0800.291
a-	All measures in Term vs. Preterm groups are adjusted for age and race.
* - T-test for continuous variables and ANCOVA for lab measures
** - Non-normally distributed data and Wilcoxon Signed-Rank Test for non-parametric
*** - Log transformed and then exponentiated (mean, lower and upper mean values)
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